First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

Overview of attention for article published in Journal for Immunotherapy of Cancer, July 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 27 Dimensions

Readers on

mendeley: 50 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 11 X posts from 6 X users, with an upper bound of 28,021 followers.

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors https://t.co/oQYs9nUa3D

28 Aug 2019

Reply Repost Favourite

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. - PubMed - NCBI https://t.co/yxCuIQDI19

28 Aug 2019

Reply Repost Favourite

RT @sitcancer: #JITC Research: First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients w…

20 Aug 2019

Reply Repost Favourite

#JITC Research: First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors https://t.co/Xv9HJwN6jn https://t.co/jvqYo0Gutw

20 Aug 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 7 additional X posts.